GLP-1 medications have quickly become one of the most talked-about developments in healthcare. Originally developed to help manage type 2 diabetes, these medications are now widely used to support weight loss and improve metabolic health. As their popularity continues to grow, ongoing health monitoring is often left out of the conversation.
For many patients, success with a GLP-1 medication is measured by the number on the scale. While weight loss can be a meaningful indicator of progress, it is only one piece of a much larger picture. The body’s response to treatment involves changes in blood sugar regulation, cholesterol levels, liver and kidney function, electrolyte balance, and other important health markers that are not visible from day to day.
Routine laboratory testing can help patients and healthcare providers understand changes to the body’s metabolic pathways, determine whether treatment is effective, and identify potential concerns early. For example, blood glucose and hemoglobin A1c testing can help track how well blood sugar is being managed over time. Lipid testing may reveal improvements in cholesterol and triglyceride levels that often accompany weight loss and better metabolic health. Comprehensive metabolic testing can provide information about liver function, kidney health, and electrolyte balance, all of which are important to monitor during long-term medication use.
To fill this testing gap, Sonora Quest recently launched the GLP-1 Progress Panel, available to patients without a doctor’s order through My Lab Request™. The panel combines several commonly monitored tests, including blood sugar, cholesterol, thyroid and metabolic health markers, into a single offering designed to help patients better understand how their body is responding to GLP-1 use over time.
Results from this panel can be used to support conversations between patients and their healthcare providers. Healthcare decisions are most effective when they are guided by objective data, and laboratory results can help provide context for how a patient is responding to treatment. In some cases, testing may indicate that additional evaluation is needed or that a treatment plan should be adjusted. In others, results may offer reassurance that progress is occurring beyond what can be seen on the scale.
Patients taking GLP-1 medications should continue working closely with their healthcare providers to interpret results and make informed decisions about treatment. Whether through Sonora Quest’s GLP-1 Progress Panel or another laboratory testing option, access to regular health data can empower individuals to take a more active role in understanding their health.
The growing use of GLP-1 medications reflects an important shift in how obesity, diabetes and metabolic health are being addressed. As treatment options evolve, the importance of monitoring should evolve alongside them. Better health outcomes are not determined solely by the medications patients take, but by how well they understand the changes happening within their bodies along the way.
Dr. Kelly Wilhelms, Scientific Director at Sonora Quest
